Genitourinary Cancers Symposium

Array of Treatments for Metastatic Prostate Cancer, but Can We Afford Them?
By Phoebe Starr
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
New York, NY—Men with castration-resistant prostate cancer (CRPC) now have several different treatments that improve their survival—docetaxel (Taxo-tere), cabazitaxel (Jevanta), abiraterone (Zytiga), and sipuleucel-T (Provenge).
Read Article
Two Mechanistically Distinct Agents Lead to Impressive Survival Improvements in Advanced Prostate Cancer
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—Two treatments sig­nificantly extended survival in men with metastatic castration-resistant pros­tate cancer (CRPC) in separate phase 3 clinical trials reported at the 2012 Genitourinary Cancers Symposium.
Read Article
Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer
By Wayne Kuznar
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—A new, large comparative effectiveness analysis of 3 techniques for delivering radiation therapy for the treatment of localized prostate cancer supports intensity-modulated radiation therapy (IMRT) as the current standard, said Ronald Chen, MD, MPH, Assistant Professor of Radiation Oncology, University of North Carolina (UNC), Chapel Hill, and Research Fellow, Sheps Center for Health Services Research, UNC at the 2012 annual Genitourinary Cancers Symposium.
Read Article

Page 3 of 4

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?